AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04732364 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound guided erector spinae plan block using bupivacaine for modified radical mastectomy
Description: Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
Study NCT04732364 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided erector spinae plan block with bupivacaine and Dexmetonidine for modified radical mastectomy
Description: Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
Study NCT04732364 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided erector spinae plan block with bupivacaine and magnesium slphate for modified radical mastectomy
Description: Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
Study NCT01064323 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent pneumatic compression of the lower extremities
Description: IPC will be done for 3 divided hours daily for 4 weeks
Study NCT04254835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein
Description: Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
Study NCT04254835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein
Description: Conventional Fluoride varnish
Study NCT02598258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sauna and cold water bath
Description: Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
Study NCT03777488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1 gram intramuscular
Description: Intramuscular tranexamic acid crossover to oral and intravenous arms
Study NCT02820116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: In the neoadjuvant treatment phase, eligible patients will receive 125mg of Icotinib three times per day for 8 weeks (56 days). In the post-surgery phase, Icotinib 125mg/three tims/day taken orally for 2 years or till disease progression or unacceptable toxicity.
Study NCT01300650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra 100 mg subcutaneous injection daily
Study NCT01500018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg
Study NCT02944032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CogmedRM
Description: Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. Difficulty of the tasks is automatically adjusted on a trial-by-trial basis throughout each training session to match a child's current working memory span, such that as the child becomes more proficient, the exercises become more difficult. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
Study NCT01500018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg
Study NCT01566968 — intervention group
Intervention type: OTHER
Intervention: Cough challenge test
Description: Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.
Study NCT01566968 — intervention group
Intervention type: OTHER
Intervention: 24 hour ambulatory cough recording
Description: Cough recording by using an ambulatory sound recording device.
Study NCT01566968 — intervention group
Intervention type: OTHER
Intervention: Cough quality of life questionnaire
Description: questionnaire designed to assess impact of cough on a person's life
Study NCT02944032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobymax
Description: MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period.
Study NCT02428517 — intervention group
Intervention type: PROCEDURE
Intervention: AlloHCT for Young/MSD
Description: Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
Study NCT02428517 — intervention group
Intervention type: PROCEDURE
Intervention: AlloHCT for Young/MUD&FMD
Description: Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
Study NCT02428517 — intervention group
Intervention type: PROCEDURE
Intervention: AlloHCT for Old/MSD
Description: Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
Study NCT02428517 — intervention group
Intervention type: PROCEDURE
Intervention: AlloHCT for Old/MUD&FMD
Description: Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
Study NCT02599714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
Study NCT02599714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: cyclin dependent kinase inhibitor
Study NCT02599714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant hormonal therapy as background
Study NCT02556554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 or G5 Platinum CGM system
Description: Intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy
Study NCT02556554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 or G5 Platinum CGM system with Share
Description: Treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™
Study NCT02951065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tooth brush without nylon bristles
Description: Subjects will use a bristle-less tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
Study NCT02951065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tooth brush with soft nylon bristles
Description: Subjects will use a soft bristled tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
Study NCT03651869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette 1
Description: Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
Study NCT03651869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette 2
Description: Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
Study NCT03651869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patch 1
Description: A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Study NCT03651869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patch 2
Description: A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Study NCT01334164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Management Checkups
Description: Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
Study NCT01334164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outcome Monitoring
Description: Outcome monitoring only, however participates are still able (and do) enter treatment on their own
Study NCT01577680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GSK573719/vilanterol
Description: All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1
Study NCT01577680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GSK573719
Description: All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
Study NCT01133873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (XP20C)
Description: 100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified
Study NCT01133873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 times a day in ascending doses until a maximum tolerated dose is identified
Study NCT01500018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg
Study NCT04489628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 or Placebo
Description: ): Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
Study NCT04489628 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Doctella telehealth monitoring
Description: Doctella device will be give to participants by the Emergency department as part of usual care to monitor heart rate, respiratory rate, oxygen saturation, and perfusion index vitals continuously for approximately 10 days. The study team will receive the vitals signs data (heart rate, respiratory rate, oxygen saturation, perfusion index, and temperature) retrospectively and will not be able to monitor patients in real time.
Study NCT04489628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Doctella telehealth monitoring
Description: Doctella device will be give to participants by the Emergency department as part of usual care to monitor heart rate, respiratory rate, oxygen saturation, and perfusion index vitals continuously for approximately 10 days. The study team will receive the vitals signs data (heart rate, respiratory rate, oxygen saturation, perfusion index, and temperature) retrospectively and will not be able to monitor patients in real time.
Study NCT00440011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03% eye drops
Description: bimatoprost 0.03% 1 drop nightly for 3 months
Study NCT00440011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost 0.004% eye drops
Description: travoprost 0.004% 1 drop nightly for 3 months
Study NCT03487848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Specified dose on specified days for specified duration
Study NCT03872635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral carbohydrate liquid
Description: patients undergoing neoadjuvant chemotherapy and radical hysterectomy with bilateral pelvic lymph node dissection were randomized to receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
Study NCT04030533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (SC): Dose 1
Description: Participants will receive a single dose of guselkumab (dose 1) subcutaneously.
Study NCT04030533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (SC): Dose 2
Description: Participants will receive a single dose of guselkumab (dose 2) subcutaneously.
Study NCT04030533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (IV): Dose 1
Description: Participants will receive a single IV infusion of guselkumab (dose 1).
Study NCT02564237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StreptAnova™ (Group A streptococcal (GAS) vaccine)
Description: StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
Study NCT04030533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (IV): Dose 2
Description: Participants will receive a single IV infusion of guselkumab (dose 2).
Study NCT04030533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 6 mg/mL
Description: Participants will receive a single IV infusion of ustekinumab 6 mg/mL solution.
Study NCT03487848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Specified dose on specified days for specified duration
Study NCT01519102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual Hormone closed-loop system
Description: The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
Study NCT02162355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634 50 mg
Description: 2 tablets of 25 mg GLPG0634 once daily for 10 days
Study NCT03281616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Individually tailored diets; 30% caloric reduction according to daily energy requirements measured by indirect calorimetry
Study NCT04266912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT02162355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634 100 mg
Description: 1 tablet of 100 mg GLPG0634 once daily for 10 days
Study NCT02162355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634 200 mg
Description: 2 tablets of 100 mg GLPG0634 once daily for 10 days
Study NCT02162355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 or 2 matching placebo tablets once daily for 10 days
Study NCT02564237 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
Study NCT02564237 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
Study NCT02564237 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Papillomavirus vaccine
Description: Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
Study NCT02323867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Beta T cell depletion
Study NCT01186471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A643 (nicotine)
Description: 1mg oromucosal nicotine spray- three times daily during each treatment period
Study NCT01186471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A643 (nicotine)
Description: 2mg oromucosal nicotine spray- three times daily during each treatment period
Study NCT01186471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo - three times daily during each treatment period
Study NCT04266912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV
Study NCT01241916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static-Progressive Splint
Description: Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.
Study NCT01241916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Splint
Description: Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.
Study NCT01320657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket
Description: Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks.
Study NCT01320657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket
Description: Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks.
Study NCT01320657 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket
Description: Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks.
Study NCT04128319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-Guard
Description: Patients will receive 4 doses of T-Guard treatment, administered intravenously as four 4-hour infusions at least two calendar days (no less than 40 hours) apart. Each dose consists of 4 mg/m\^2 Body Surface Area (BSA).
Study NCT02615210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOC-directed biopsies using the SpyGlass System
Description: The cholangioscopy procedure with the SpyGlass System is performed by a single operator with the SpyScope Access and Delivery Catheter positioned just below the operating channel of the duodenoscope. SpyBite Biopsy Forceps guided by the SpyScope Catheter are introduced and endoscopic-guided biopsy is taken at the level of the stricture. Target lesions will be identified under direct visualization using the SOC system, and 6-8 bites will be performed with the SpyBite forceps. Once SOC-directed biopsies are obtained, the SOC system will be withdrawn into the working channel of the duodenoscope and removed Patient will be contacted monthly to determine if they have undergone any additional procedures and to record potential adverse events.
Study NCT01673555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863